Key facts
- This page summarizes Ting Xiao's Form 4/A - Amendment filing for Zenas BioPharma, Inc. (ZBIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Apr 2025, 07:07.
Ting Xiao - 07 Feb 2025 Form 4/A - Amendment Insider Report for Zenas BioPharma, Inc. (ZBIO)
- Reporting relationship
- Director
- Issuer ticker
- ZBIO
- Reported as of
- 07 Feb 2025
- Net transaction value
- +$77,600
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 28 Apr 2025, 07:07:52 UTC
- Original report date
- 11 Feb 2025
- Prior SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Chase Jayasekera, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ting Xiao filed Form 4/A - Amendment for Zenas BioPharma, Inc. (ZBIO) on 28 Apr 2025.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: +$77,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZBIO
transaction
Common Stock
Purchase
- Transaction value
- $77,600
- Shares
- +10,000
- Change %
- Price
- $7.76
- Shares after
- 10,000
- Date
- 07 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $7.64 to $7.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Footnote F2
This Form 4/A is filed solely to amend the previous Form 4 filed by the Reporting Person on February 11, 2025, which incorrectly reported in column 5 of Table I the amount of securities beneficially owned following reported transactions as 47,000 shares. The correct amount of securities beneficially owned following the reported transactions is 10,000 shares.